Feed MGNX
MG

MacroGenics, Inc.

MGNX · NASDAQ

$4.12 -1.20% (-$0.05)
1M +2.49%
Market Cap $261.9M
P/E Ratio -
Div. Yield -
ROE 31.27%

Bulios Fair Price

$3.09

25.0% downside

Current Price

$4.12

Undervalued Fair Value Overvalued

According to Bulios Fair Price, MGNX is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
1/9
Valuation
57 /100
Fair
P/S 1.56x
P/B 6.11x
P/E N/A
Growth
15 /100
Declining
Rev. growth 0.12%
Book val. growth 26.85%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 50.44%
FCF margin 39.09%
Net margin 8.70%
Quality
6 /100
Poor
ROIC 2.36%
Asset turnover 0.49x
ROE 31.27%
Debt
51 /100
Moderate
Debt/Equity 0.82x
Int. coverage -5.19x
Current ratio 2.96x
Stability
16 /100
Unstable
Beta 1.23x
Profitable years 0
Rev. volatility 114.03%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about MGNX
Online

About the company

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Eric Risser

Employees

293

Headquarters

Rockville

Upcoming events

11 NOV

Earnings

Upcoming earnings report

50d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.